Europe
Roche hopes to advance the development of its own nanopore sequencer, which would use a new approach combining electronic and biological components to sequence DNA quickly and at low cost.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 22, 2020.
Affärsvärlden’s IPO Guide announced that FluoGuide A/S won the 2019 share price development award in the micro-cap category and also received the honorary quality award.
Pharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
A high dose of filgotinib, the JAK1 inhibitor under long-term development by Gilead Sciences and Galapagos NV, proved effective in a Phase IIb/III study as a treatment for patients with moderately to severely active ulcerative colitis.
The U.S. Biomedical Advanced Research and Development Authority (BARDA) paid more than $1 billion to support the development, production and delivery of the vaccine beginning this fall.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
Weeks after Mammoth Biosciences announced its CRISPR-based diagnostics test for COVID-19 had a high degree of specificity even for asymptomatic patients, the company has struck a deal with GSK to accelerate development of the test in hopes of getting them in consumer hands as soon as possible.
Clovis Oncology’s Rubraca remained the only PARP inhibitor approved for prostate cancer for only a handful of days. Today, that medication is joined by AstraZeneca’s and Merck’s powerhouse PARP inhibitor, Lynparza.
PRESS RELEASES